Stockreport

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants [Yahoo! Finance]

NewAmsterdam Pharma Company N.V. - Ordinary Shares  (NAMS) 
PDF late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lip [Read more]